ReviewFrontiers in neuroscience2015
The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events.
Review in Frontiers in neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Application of resting-state EEG theta /alpha power ratio analysis for diagnosing amnestic mild cognitive impairment.Scientific reports · 2026Article
- Diagnostic and prognostic utility of serum β-synuclein in Alzheimer's disease: a longitudinal cohort study.The journal of prevention of Alzheimer's disease · 2026Article
- Gut microbiota: A new window for the prevention and treatment of neuropsychiatric disease.Journal of central nervous system disease · 2025Review
- Blood-based biomarkers in Alzheimer's disease: a mini-review.Metabolic brain disease · 2023Review
- Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease?Molecules (Basel, Switzerland) · 2022Review
- Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers.Arquivos de neuro-psiquiatria · 2022Review
- Sagacious confucius' pillow elixir ameliorates Dgalactose induced cognitive injury in miceFrontiers in pharmacology · 2022Article
- Cerebrospinal Fluid of Patients With Alzheimer's Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles.Frontiers in aging neuroscience · 2021Article
- Alterations of aqueous humor Aβ levels in Aβ-infused and transgenic mouse models of Alzheimer disease.PloS one · 2020Article
- CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.Alzheimer's research & therapy · 2019Article
- Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.Journal of neurochemistry · 2019Review
- Microvesicles from cerebrospinal fluid of patients with Alzheimer's disease display reduced concentrations of tau and APP protein.Scientific reports · 2019Article
- Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults.Brain imaging and behavior · 2019Observational
- The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease.Alzheimer's research & therapy · 2018Article
- Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Article
- Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.Alzheimer's research & therapy · 2018Article
- Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias.Focus (American Psychiatric Publishing) · 2018Review
- The Neurotoxic Role of Extracellular Tau Protein.International journal of molecular sciences · 2018Review
- Neurogranin as a predictor of memory and executive function decline in MCI patients.Neurology · 2018Article
- A Specific Reduction in AβFrontiers in aging neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper gives a short review on cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD), from early developments to high-precision validated assays on fully automated lab analyzers. We also discuss developments on novel biomarkers, such as synaptic proteins and Aβ oligomers. Our vision for the future is that assaying a set of biomarkers in a single CSF tube can monitor the whole spectrum of AD molecular pathogenic events. CSF biomarkers will have a central position not only for clinical diagnosis, but also for the understanding of the sequence of molecular events in the pathogenic process underlying AD and as tools to monitor the effects of novel drug candidates targeting these different mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.